Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy

Neuro-Oncology

Volumn 12, Issue 6, 2010, Pages 595-602

  Beauchesne, Patrick ^a   Bernier, Valerie ^b   Carnin, Charlotte ^a   Taillandier, Luc ^a   Djabri, Mohamed ^e   Martin, Laurent ^g   Michel, Xavier ^c   Maire, Jean Philippe ^d   Khalil, Toufic ^f   Kerr, Christine ^h   Gorlia, Thierry ⁱ   Stupp, Roger ^j   Pedeux, Remy ^k  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b Centre A Vautrin   (France)

^c Centre Hospitalier Régional de Metz Thionville   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e CHG de Thionville   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^g Centre G le Conquérant le Havre   (France)

^h CENTRE VAL D AURELLE   (France)

ⁱ EORTC DATA CENTER   (Belgium)

^j LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^k INSERM U917   (France)

more..

Author keywords

Glioblastoma; Inoperable; Low doses; Radiation therapy; Ultrafractionated regimen

Indexed keywords

CORTICOSTEROID; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; IRRADIATION; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; SURVIVAL RATE;

EID: 77957097605     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq008     Document Type: Article

References (33)

1. Behin A, Hoang-Xuan K, Carpentier AF, et al. Primary brain tumours in adults. Lancet. 2003;361:323-331.
2. Black PM. Brain tumor. Part 2. N Engl J Med. 1991;324:1555-1564.
3. Black PM. Brain tumors. Part 1. N Engl J Med. 1991;324:1471-1476.
4. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114-123.
5. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-2597.
6. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011-1018.
7. Joiner MC, Denekamp J, Maughan RL. The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;49:565-580.
8. Joiner MC, Marples B, Lambin P, et al. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 2001;49:379-389.
9. Lambin P, Malaise EP, Joiner MC. The effect of very low radiation doses on the human bladder carcinoma cell line RT112. Radiother Oncol. 1994;32:63-72.
10. Lambin P, Malaise EP, Joiner MC. Might intrinsic radioresistance of human tumour cells be induced by radiation? Int J Radiat Biol. 1996;69:279-290.
11. Lambin P, Marples B, Fertil B, et al. Hypersensitivity of a human tumour cell line to very low radiation doses. Int J Radiat Biol. 1993;63:639-650.
12. Marples B, Lam GK, Zhou H, et al. The response of Chinese hamster V79-379A cells exposed to negative pi-mesons: evidence that increased radioresistance is dependent on linear energy transfer. Radiat Res. 1994;138:S81-S84.
13. Marples B, Lambin P, Skov KA, et al. Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol. 1997;71:721-735.
14. Short SC, Kelly J, Mayes CR, et al. Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol. 2001;77:655-664.
15. Short SC, Mitchell SA, Boulton P, et al. The response of human gliomacell lines to low-dose radiation exposure. Int J Radiat Biol. 1999;75:1341-1348.
16. Beauchesne PD, Bertrand S, Branche R, et al. Human malignant glioma cell lines are sensitive to low radiation doses. Int J Cancer. 2003;105:33-40.
17. McDonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
18. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
19. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
20. Berg G, Blomquist E, Cavallin-Stahl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol. 2003;42:582-588. (Pubitemid 37193846)
21. Walker MD, Alexander E, Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-343.
22. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323-1329.
23. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649-652.
24. Scott CB, Scarantino C, Urtasun R, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998;40:51-55.
25. Dische S, Saunders MI. Continuous, hyperfractionated, accelerated radiotherapy (CHART). Br J Cancer. 1989;59:325-326.
26. Payne DG, Simpson WJ, Keen C, et al. Malignant astrocytoma: hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial. Cancer. 1982;50: 2301-2306.
27. Ludgate CM, Douglas BG, Dixon PF, et al. Superfractionated radiotherapy in grade III, IV intracranial gliomas. Int J Radiat Oncol Biol Phys. 1988;15:1091-1095.
28. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys. 1989;16:1389-1396.
29. Horiot JC, van den Bogaert W, Ang KK, et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. Front Radiat Ther Oncol. 1988;22:149-161.
30. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer. 1996;15:1535-1543.
31. Brada M, Baumert B. Focal fractionated conformal stereotactic boost following conventional radiotherapy of high-grade gliomas: a randomized phase III study. A joint study of the EORTC (22972) and the MRC (BR10). Front Radiat Ther Oncol. 1999;33:241-243.
32. Simpson WJ, Platts ME. Fractionation study in the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1976;1:639-644.
33. Keim H, Potthoff PC, Schmidt K, et al. Survival and quality of life after continuous accelerated radiotherapy of glioblastomas. Radiother Oncol. 1987;9:21-26.